Comparative Pharmacology
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5 IN PLASTIC CONTAINER versus INOCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5 IN PLASTIC CONTAINER versus INOCOR.
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER vs INOCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-1 adrenergic receptors of the heart, increasing contractility and cardiac output. It also has mild beta-2 and alpha-1 receptor activity.
Inocor (amrinone) is a phosphodiesterase III inhibitor that increases intracellular cAMP in cardiac and vascular smooth muscle, leading to positive inotropic effects and vasodilation.
Continuous IV infusion: 2.5 to 20 mcg/kg/min; titrate to desired hemodynamic response. Maximum dose: 40 mcg/kg/min.
Initial intravenous bolus of 0.75 mg/kg over 2-3 minutes, followed by a continuous infusion of 5-10 mcg/kg/min. Maximum dose: 10 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2 minutes for the parent drug (dobutamine) due to rapid metabolism by COMT. In clinical context, the effect half-life is about 2–3 minutes, requiring continuous intravenous infusion to maintain steady-state concentrations.
Terminal elimination half-life: 2.4 hours in normal renal function; prolonged in renal impairment (up to 6 hours in ESRD).
Primarily renal excretion of metabolites (catechol-O-methyltransferase conjugates) and unchanged drug: approximately 80% renal, 20% biliary/fecal. Less than 5% excreted unchanged in urine.
Primarily renal (80%) as unchanged drug; 20% biliary/fecal.
Category C
Category C
Inotropic Agent
Inotropic Agent